Nafamostat mesylate

Nafamostat mesylate
Product Description

Nafamostat mesylate is a treatment for anticoagulant for acute pancreatitis that has shown steady growth since it was released domestically in 2004.It was mainly used in several Asian countries and recorded sales of 14.4 billion won in Korea in 2019. Our company has registered KDMF for the first time among Generic APIs. (August 2014) And We produce high purity Nafamostat mesilate and supply it to many pharmaceutical companies in Korea. In July of this year, our research institute developed its own manufacturing method and applied for a patent.It is also drawing attention as a drug-regenerating substance as it shows the possibility of corona treatment.Nafamostat showed an antiviral effect “hundreds of times” higher than Remdesivir in human lung cells. Hence, there are many clinical trials of Nafamostat in progress in the world.

KUKJEON

  • KR
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company

KUKJEON

  • KR
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company

More Products from KUKJEON (1)

  • Itopride HCl

    Product Itopride HCl

    Itopride hydrochloride is a functional indigestion treatment mainly used in Korea and Japan. Our company holds its own patent on how to manufacture itoprid, and it has obtained MF approval not only in Korea but also in Japan's PMDA and exports high-quality itoprid hydrochloride to Japanese pharmaceutical c...